Irritable bowel syndrome with constipation (IBS-C) significantly impacts patients, not only with its physical symptoms of persistent constipation, abdominal pain, and bloating, but also through a considerable psychological and social burden. IBS-C has a multifactorial pathophysiology that includes altered gastrointestinal motility, visceral hypersensitivity, dysregulated brain-gut interactions, and microbiome-immune imbalances. This complexity requires a comprehensive understanding of IBS-C to effectively manage the care of patients. Traditional treatments often fall short of addressing the full scope of these interconnected mechanisms, leaving many patients with suboptimal symptom control and a diminished quality of life. Our symposium will provide practical and engaging discussions to help you better understand the impact of IBS-C on your patients’ quality of life, the pathophysiology behind the disease, and the clinical data supporting the use of new treatment options.
This program is not affiliated with Digestive Disease Week®
Innovative Approaches to IBS-C: Personalized Treatment for Better Outcomes
While attending DDW 2025, join us to discover the impact of IBS-C on patients’ QoL and find out how to apply advances in its treatment & management.
This broadcast will start in exactly:
- 0
Day(s)
- 0
Hour(s)
- 0
Minute(s)
- 0
Second(s)
Overview
Program Schedule*
6:30pm – 6:35pm: Welcome and Introductions
6:35pm – 6:50pm: Understanding the Full Impact of IBS-C: Patient Quality of Life and the Limitations of Current IBS-C Management Strategies
6:50pm – 7:05pm: The Science Behind IBS-C: Linking Pathophysiology to Treatment
7:05pm – 7:20pm: New Horizons in IBS-C Treatment: Assessing FDA-Approved Medications
7:20pm – 7:30pm: Conclusion and Audience Q&A Session
*Subject to changeDisclosure of Conflicts of Interest
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Chair:
Darren M. Brenner, MD, AGAF, FACG, RFF
Professor of Medicine
Northwestern University
Chicago, IL
Dr. Brenner has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: AbbVie, Anji, Ardelyx, Bayer, Blueprint Meds, CinPhloro, Dr. Reddy, Gemelli, Ironwood, Laborie, Mahana, Salix, Vibrant
Ownership Interest: Owlstone Pharma
Faculty:
William D. Chey, MD, AGAF, FACG, FACP, RFF
H. Marvin Pollard Professor of Gastroenterology
Professor of Nutrition Sciences
Chief, Division of Gastroenterology
Michigan Medicine
Ann Arbor, MI
Dr. Chey has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: AbbVie, ACG, Ardelyx, Biomerica, Gemelli, GI Health Foundation, IFFGD, Ironwood, Nestle, QOL Medical, Phathom, RedHill, Rome, Salix/Valeant, Takeda, Vibrant
Research: Commonwealth Diagnostics International, FDA, NIH, Salix/Valeant
Ownership Interest: Coprata, Dieta, Evinature, FoodMarble, Kiwi Bioscience, ModifyHealth
Patent Holder: My Nutrition Health, Digital Manometry, Rectal Expulsion Device
Kimberly D. Orleck, PA-C
Director of Advanced Practice Providers
Atlanta Gastroenterology Associates
Atlanta, GA
Ms. Orleck has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: AbbVie, Ardelyx, Janssen, Lilly, Pfizer, Salix, Takeda
Reviewers/Content Planners/Authors:- Cindy Davidson has no relevant relationships to disclose.
- Brian P. McDonough, MD, FAAFP, has no relevant relationships to disclose.
- Rosanne Strauss, PharmD, has no relevant relationships to disclose.
Learning Objectives
After participating in this educational activity, participants should be better able to:
- Assess the comprehensive and significant impact of irritable bowel syndrome with constipation (IBS-C) on patients' overall quality of life
- Understand the multifactorial pathophysiology of IBS-C and its effects on treatment outcomes
- Evaluate the efficacy and safety of the new FDA-approved medications for IBS-C
Target Audience
This activity has been designed to meet the educational needs of gastroenterologists as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare providers involved in managing patients with irritable bowel syndrome with constipation (IBS-C).
Accreditation and Credit Designation Statements
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Global Learning Collaborative (GLC) designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.0 nursing contact hour(s). Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.0 contact hour(s)/0.1 CEUs of pharmacy contact hour(s).
The Universal Activity Number for this program is UAN JA0006235-0000-25-017-L01-P. This learning activity is application-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).
Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit(s) for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit(s). PAs should claim only the credit commensurate with the extent of their participation in the activity.Provider(s)/Educational Partner(s)
Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.
Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the best education in the most impactful manner and to verify its results with progressive outcomes research.
Commercial Support
This activity is supported by an independent educational grant from Ardelyx, Inc.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Overview
Irritable bowel syndrome with constipation (IBS-C) significantly impacts patients, not only with its physical symptoms of persistent constipation, abdominal pain, and bloating, but also through a considerable psychological and social burden. IBS-C has a multifactorial pathophysiology that includes altered gastrointestinal motility, visceral hypersensitivity, dysregulated brain-gut interactions, and microbiome-immune imbalances. This complexity requires a comprehensive understanding of IBS-C to effectively manage the care of patients. Traditional treatments often fall short of addressing the full scope of these interconnected mechanisms, leaving many patients with suboptimal symptom control and a diminished quality of life. Our symposium will provide practical and engaging discussions to help you better understand the impact of IBS-C on your patients’ quality of life, the pathophysiology behind the disease, and the clinical data supporting the use of new treatment options.
This program is not affiliated with Digestive Disease Week®Program Schedule*
6:30pm – 6:35pm: Welcome and Introductions
6:35pm – 6:50pm: Understanding the Full Impact of IBS-C: Patient Quality of Life and the Limitations of Current IBS-C Management Strategies
6:50pm – 7:05pm: The Science Behind IBS-C: Linking Pathophysiology to Treatment
7:05pm – 7:20pm: New Horizons in IBS-C Treatment: Assessing FDA-Approved Medications
7:20pm – 7:30pm: Conclusion and Audience Q&A Session
*Subject to changeDisclosure of Conflicts of Interest
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Chair:
Darren M. Brenner, MD, AGAF, FACG, RFF
Professor of Medicine
Northwestern University
Chicago, IL
Dr. Brenner has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: AbbVie, Anji, Ardelyx, Bayer, Blueprint Meds, CinPhloro, Dr. Reddy, Gemelli, Ironwood, Laborie, Mahana, Salix, Vibrant
Ownership Interest: Owlstone Pharma
Faculty:
William D. Chey, MD, AGAF, FACG, FACP, RFF
H. Marvin Pollard Professor of Gastroenterology
Professor of Nutrition Sciences
Chief, Division of Gastroenterology
Michigan Medicine
Ann Arbor, MI
Dr. Chey has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: AbbVie, ACG, Ardelyx, Biomerica, Gemelli, GI Health Foundation, IFFGD, Ironwood, Nestle, QOL Medical, Phathom, RedHill, Rome, Salix/Valeant, Takeda, Vibrant
Research: Commonwealth Diagnostics International, FDA, NIH, Salix/Valeant
Ownership Interest: Coprata, Dieta, Evinature, FoodMarble, Kiwi Bioscience, ModifyHealth
Patent Holder: My Nutrition Health, Digital Manometry, Rectal Expulsion Device
Kimberly D. Orleck, PA-C
Director of Advanced Practice Providers
Atlanta Gastroenterology Associates
Atlanta, GA
Ms. Orleck has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: AbbVie, Ardelyx, Janssen, Lilly, Pfizer, Salix, Takeda
Reviewers/Content Planners/Authors:- Cindy Davidson has no relevant relationships to disclose.
- Brian P. McDonough, MD, FAAFP, has no relevant relationships to disclose.
- Rosanne Strauss, PharmD, has no relevant relationships to disclose.
Learning Objectives
After participating in this educational activity, participants should be better able to:
- Assess the comprehensive and significant impact of irritable bowel syndrome with constipation (IBS-C) on patients' overall quality of life
- Understand the multifactorial pathophysiology of IBS-C and its effects on treatment outcomes
- Evaluate the efficacy and safety of the new FDA-approved medications for IBS-C
Target Audience
This activity has been designed to meet the educational needs of gastroenterologists as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare providers involved in managing patients with irritable bowel syndrome with constipation (IBS-C).
Accreditation and Credit Designation Statements
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Global Learning Collaborative (GLC) designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.0 nursing contact hour(s). Nurses should claim only the credit commensurate with the extent of their participation in the activity.Global Learning Collaborative (GLC) designates this activity for 1.0 contact hour(s)/0.1 CEUs of pharmacy contact hour(s).
The Universal Activity Number for this program is UAN JA0006235-0000-25-017-L01-P. This learning activity is application-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).
Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit(s) for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit(s). PAs should claim only the credit commensurate with the extent of their participation in the activity.Provider(s)/Educational Partner(s)
Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.
Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the best education in the most impactful manner and to verify its results with progressive outcomes research.
Commercial Support
This activity is supported by an independent educational grant from Ardelyx, Inc.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Recommended
Advancing TROP-2-Targeted ADCs in HR+ Breast Cancer: Navigating Today and Shaping Tomorrow
Advancing TROP-2-Targeted ADCs in HR+ Breast Cancer: Navigating Today and Shaping Tomorrow
CME/CEAdvancing TROP-2-Targeted ADCs in HR+ Breast Cancer: Navigating Today and Shaping Tomorrow
0.50 credits
Javier Cortes, MD, PhD
Hope S. Rugo, MD, FASCO
0.50 creditsThe Safety of Sodium Oxybate in Treating Narcolepsy
The Safety of Sodium Oxybate in Treating Narcolepsy
CME/CEThe Safety of Sodium Oxybate in Treating Narcolepsy
0.50 creditsClete A. Kushida, MD, PhD
Sally Ibrahim, MD, FAAP
0.50 creditsPatient Partners in NSCLC: Collaborating to Enhance Quality of Life and Outcomes With EGFRi-Associated Dermatologic Toxicities
Patient Partners in NSCLC: Collaborating to Enhance Quality of Life and Outcomes With EGFRi-Associated Dermatologic Toxicities
CME/CEPatient Partners in NSCLC: Collaborating to Enhance Quality of Life and Outcomes With EGFRi-Associated Dermatologic Toxicities
0.25 creditsJonathan Leventhal, MD
Shahnaz Singh-Kandah, NP
0.25 credits